These compelling results led to a rapid update of the American Society of Clinical Oncology (ASCO) guideline and a positive opinion of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommending the use of T-DXd in patients with HER2-low metastatic BC [38,39]. This evidence concerns the gene ERBB2 and breast cancer.